Clinical Trial Results:
            Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for 8 weeks in out-patients with severe Major Depressive Disorder. A randomised double-blind, parallel groups, international study versus fluoxetine (20 mg/day with potential adjustment to 40 mg) with a double-blind extension period of 16 weeks.
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2004-004008-19 | 
    Trial protocol  | 
        GB IT ES | 
    Global completion date  | 
        
                                    14 Mar 2008
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    06 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    03 May 2014
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                Synopsis dated 10 march 2009 | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.